二次手术在复发性卵巢癌中的作用。
The role of secondary surgery in recurrent ovarian cancer.
作者信息
Lorusso D, Mancini M, Di Rocco R, Fontanelli R, Raspagliesi F
机构信息
Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy.
出版信息
Int J Surg Oncol. 2012;2012:613980. doi: 10.1155/2012/613980. Epub 2012 Aug 5.
Abstract
Despite optimal treatment (complete cytoreduction and adjuvant chemotherapy), 5-year survival for advanced ovarian cancer is approximately 30% and most patients succumb to their disease. Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer but its role in recurrent disease is controversial and remains a field of discussion mainly owing to missing data from prospective randomized trials. A critical review of literature evidence on secondary surgery in recurrent ovarian cancer will be described.
摘要
尽管进行了最佳治疗（完全细胞减灭术和辅助化疗），晚期卵巢癌的5年生存率约为30%，大多数患者最终死于该疾病。细胞减灭术被公认为原发性卵巢癌的主要治疗方法，但其在复发性疾病中的作用存在争议，仍是一个主要因前瞻性随机试验数据缺失而有待讨论的领域。本文将对复发性卵巢癌二次手术的文献证据进行批判性综述。
相似文献
1
The role of secondary surgery in recurrent ovarian cancer.二次手术在复发性卵巢癌中的作用。
Int J Surg Oncol. 2012;2012:613980. doi: 10.1155/2012/613980. Epub 2012 Aug 5.
2
Optimal primary surgical treatment for advanced epithelial ovarian cancer.晚期上皮性卵巢癌的最佳初次手术治疗
Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD007565. doi: 10.1002/14651858.CD007565.pub2.
3
Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.减瘤手术联合化疗与单纯化疗治疗复发性铂敏感上皮性卵巢癌（SOCceR试验）：一项多中心随机对照研究
BMC Cancer. 2014 Jan 14;14:22. doi: 10.1186/1471-2407-14-22.
4
The current role of secondary cytoreductive surgery for recurrent ovarian cancer.二次减瘤手术在复发性卵巢癌中的当前作用。
Front Oncol. 2022 Oct 21;12:1029976. doi: 10.3389/fonc.2022.1029976. eCollection 2022.
5
Critical evaluation of secondary cytoreduction in recurrent ovarian cancer.复发性卵巢癌二次肿瘤细胞减灭术的批判性评估
Gynecol Oncol. 2004 Nov;95(2):273-80. doi: 10.1016/j.ygyno.2004.09.018.
6
7
8
Survival Impact of Secondary Cytoreductive Surgery for Recurrent Ovarian Cancer in an Asian Population.二次减瘤手术对亚洲人群复发性卵巢癌生存的影响
Oman Med J. 2015 Sep;30(5):344-52. doi: 10.5001/omj.2015.70.
9
Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers.晚期低级别浆液性卵巢癌：两个大型肿瘤中心手术及化疗管理的回顾性分析
Front Oncol. 2022 Sep 27;12:970918. doi: 10.3389/fonc.2022.970918. eCollection 2022.
10
Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.二次细胞减灭术——铂类敏感复发性卵巢癌治疗的可行选择。
Eur J Obstet Gynecol Reprod Biol. 2018 Sep;228:154-160. doi: 10.1016/j.ejogrb.2018.06.036. Epub 2018 Jun 20.
引用本文的文献
1
Surgery in platinum-resistant recurrent epithelial ovarian carcinoma.铂耐药复发性上皮性卵巢癌的手术治疗
World J Clin Cases. 2022 Apr 26;10(12):3739-3753. doi: 10.12998/wjcc.v10.i12.3739.
2
Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer.尼拉帕利、奥拉帕利和贝伐单抗作为新诊断晚期卵巢癌患者维持治疗的网状Meta分析及非锚定人群校正间接治疗比较的可行性研究
Cancers (Basel). 2022 Mar 2;14(5):1285. doi: 10.3390/cancers14051285.
3
MicroRNA-378a-3p contributes to ovarian cancer progression through downregulating PDIA4.miRNA-378a-3p 通过下调 PDIA4 促进卵巢癌进展。
Immun Inflamm Dis. 2021 Mar;9(1):108-119. doi: 10.1002/iid3.350. Epub 2020 Nov 7.
4
Secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: are we missing something?铂敏感复发性卵巢癌的二次肿瘤细胞减灭术：我们遗漏了什么吗？
Ann Transl Med. 2019 Dec;7(Suppl 8):S372. doi: 10.21037/atm.2019.12.94.
5
Ovarian Cancer Maintenance: Practice-Changing Data Calls for Changing Practice.卵巢癌维持治疗：改变实践的变革性数据。
Oncologist. 2019 May;24(5):576-579. doi: 10.1634/theoncologist.2019-0020. Epub 2019 Mar 20.
6
Diagnostic value of derived neutrophil-to-lymphocyte ratio in patients with ovarian cancer.中性粒细胞与淋巴细胞比值对卵巢癌患者的诊断价值。
J Clin Lab Anal. 2019 May;33(4):e22833. doi: 10.1002/jcla.22833. Epub 2019 Jan 21.
7
Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study.全身扩散加权磁共振成像在复发性卵巢癌诊断中的应用：一项临床可行性研究。
Br J Radiol. 2016 Nov;89(1067):20160468. doi: 10.1259/bjr.20160468. Epub 2016 Sep 21.
8
Benefits of fluorine-18 fludeoxyglucose positron emission tomography in secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer.氟-18氟脱氧葡萄糖正电子发射断层扫描在复发性上皮性卵巢癌患者二次肿瘤细胞减灭术中的益处。
Br J Radiol. 2015 Aug;88(1052):20150109. doi: 10.1259/bjr.20150109. Epub 2015 May 20.
9
Current approaches and challenges in managing and monitoring treatment response in ovarian cancer.卵巢癌治疗反应管理与监测的当前方法及挑战
J Cancer. 2014 Jan 1;5(1):25-30. doi: 10.7150/jca.7810.
10
Latest research and treatment of advanced-stage epithelial ovarian cancer.晚期上皮性卵巢癌的最新研究和治疗。
Nat Rev Clin Oncol. 2013 Apr;10(4):211-24. doi: 10.1038/nrclinonc.2013.5. Epub 2013 Feb 5.
本文引用的文献
1
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.早期与延迟治疗复发性卵巢癌（MRC OV05/EORTC 55955）：一项随机试验。
Lancet. 2010 Oct 2;376(9747):1155-63. doi: 10.1016/S0140-6736(10)61268-8.
2
Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer.减瘤手术联合化疗与单纯化疗治疗复发性上皮性卵巢癌的比较
Cochrane Database Syst Rev. 2010 Jun 16;2010(6):CD007822. doi: 10.1002/14651858.CD007822.pub2.
3
Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study.腹腔内热灌注化疗联合奥沙利铂巩固治疗晚期上皮性卵巢癌的前瞻性Ⅱ期多中心临床研究。CHIPOVAC 研究。
Eur J Surg Oncol. 2010 Jun;36(6):589-93. doi: 10.1016/j.ejso.2010.04.005. Epub 2010 May 13.
4
Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?卵巢癌复发的监测：生存影响还是领先时间偏倚？
Gynecol Oncol. 2010 May;117(2):336-40. doi: 10.1016/j.ygyno.2010.01.014. Epub 2010 Feb 12.
5
Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality.减瘤手术联合腹腔内热灌注化疗治疗腹膜癌病是否仍应被视为高风险手术？：一项关于发病率和死亡率的系统评价
Ann Surg. 2009 Jun;249(6):900-7. doi: 10.1097/SLA.0b013e3181a45d86.
6
Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis.复发性卵巢癌的手术治疗：腹膜癌的作用：关于腹膜癌危险因素、手术意义及预后价值的DESKTOP I试验探索性分析
Ann Surg Oncol. 2009 May;16(5):1324-30. doi: 10.1245/s10434-009-0357-0. Epub 2009 Feb 19.
7
Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis.复发性卵巢癌的细胞减灭术：一项荟萃分析
Gynecol Oncol. 2009 Jan;112(1):265-74. doi: 10.1016/j.ygyno.2008.08.033. Epub 2008 Oct 19.
8
Predictive value of PET-CT imaging versus AGO-scoring in patients planned for cytoreductive surgery in recurrent ovarian cancer.正电子发射断层显像（PET-CT）成像与AGO评分对计划进行复发性卵巢癌肿瘤细胞减灭术患者的预测价值
Eur J Obstet Gynecol Reprod Biol. 2008 Oct;140(2):263-8. doi: 10.1016/j.ejogrb.2008.05.006. Epub 2008 Jul 9.
9
Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.铂敏感复发性卵巢癌患者的二次肿瘤细胞减灭术
Ann Surg Oncol. 2007 Mar;14(3):1136-42. doi: 10.1245/s10434-006-9273-8. Epub 2006 Dec 31.
10
A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma.一项关于减瘤手术联合围手术期腹腔内化疗治疗弥漫性恶性腹膜间皮瘤疗效的系统评价。
Ann Oncol. 2007 May;18(5):827-34. doi: 10.1093/annonc/mdl428. Epub 2006 Nov 27.
Zotero 插件